US Patent 6953840 Methods of using non-human animal Apolipoprotein A-I protein
Patent 6953840 was granted and assigned to Esperion Therapeutics on October, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 5 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Nov, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+519 characters)
Article
Patent abstract
The invention provides methods and compositions for treating disorders using non-human animal Apolipoprotein A-I (ApoA-I) protein. The invention provides methods and compositions for treating disorders in animals, including humans, associated with dyslipidemia, including hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, HDL deficiency, ApoA-I deficiency, cardiovascular disease, atherosclerosis, restenosis, and other disorders such as septic shock and viral infections.
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jean-Louis Dasseux0
Lingyu Zhu0
Narendra D. Lalwani0
Date of Patent
October 11, 2005
0Patent Application Number
106298920
Date Filed
July 29, 2003
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6953840 Methods of using non-human animal Apolipoprotein A-I protein
Find more entities like US Patent 6953840 Methods of using non-human animal Apolipoprotein A-I protein
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
